Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Among virologically suppressed PWH initiating a new regimen, few individuals experienced virologic failure in real-world clinical care. While rates of regimen discontinuation were high, most discontinuations could not be attributed to a lack of virologic control or poor tolerability. These findings suggest that DTG/3TC is an effective option for ART-experienced, virologically suppressed PWH.
Authors
- Jennifer S Fusco (ORCID: https://orcid.org/0000-0003-1556-811X)
- Jean van Wyk (ORCID: https://orcid.org/0000-0001-5719-7949)
- Michael Wohlfeiler
- Supriya Sarkar (ORCID: https://orcid.org/0000-0001-8495-5039)
- Gerald Pierone (ORCID: https://orcid.org/0000-0003-0159-7243)
- Cassidy Henegar (ORCID: https://orcid.org/0000-0002-4566-1174)
- Laurence Brunet (ORCID: https://orcid.org/0000-0001-8467-4835)
- Anthony Mills (ORCID: https://orcid.org/0000-0002-6997-5581)
- Vani Vannappagari (ORCID: https://orcid.org/0000-0002-0157-9689)
- Gregory Fusco (ORCID: https://orcid.org/0000-0002-6834-784X)
Institutions
- AIDS Healthcare Foundation (US)
- Fayetteville State University (US)
- ViiV Healthcare (United Kingdom) (GB)
- Oyster Point Family Health Center (US)
- Public Health Foundation Enterprises (US)
- Electronic Product Services (Czechia) (CZ)
Publication Details
- Journal
- AIDS Research and Therapy
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1186/s12981-024-00668-7
- Citations
- 5
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- ViiV Healthcare